Xeris Biopharma Holdings (XERS) Cash from Operations (2020 - 2026)
Xeris Biopharma Holdings (XERS) posted Cash from Operations of 9870000.0 for Q1 2026, down 50.76% on a QoQ basis from 20043000.0 in Q4 2025, and up 198.39% year-over-year from 3307696.45 in Q1 2025.
Xeris Biopharma Holdings (XERS) Cash from Operations (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings' Cash from Operations history runs 7 years deep, the most recent figure standing at 9870000.0 for Q1 2026.
- Quarterly Cash from Operations rose 198.39% year-over-year to 9870000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 48527000.0 (up 281.69% YoY) and the FY2025 annual result came in at 28626000.0, up 177.41% from the prior year.
- Cash from Operations was 9870000.0 for Q1 2026 at Xeris Biopharma Holdings, down from 20043000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 20043000.0 in Q4 2025 and bottomed at 48409000.0 in Q1 2022.
- A 5-year average of 8729352.94 and a median of 10348000.0 in 2024 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations slumped 102.07% — and 2025, when it soared 914.84%.
- Xeris Biopharma Holdings' Cash from Operations stood at 16119000.0 in 2022, then soared by 146.35% to 7471000.0 in 2023, then plunged by 73.56% to 1975000.0 in 2024, then surged by 914.84% to 20043000.0 in 2025, then plunged by 50.76% to 9870000.0 in 2026.
- Business Quant data shows XERS's Cash from Operations at 9870000.0 in Q1 2026, 20043000.0 in Q4 2025, and 18432000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -40.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 401.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 463.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 388.30 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 145.80 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 13.00 Mn |
| 10 | Xeris Biopharma Holdings | 1.43 Bn | 1.32 Bn | 72.55 Mn | 9.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.87 Mn |
| Mar 31, 2026 | 9.87 Mn |
| Dec 31, 2025 | 20.04 Mn |
| Dec 31, 2025 | 20.04 Mn |
| Sep 30, 2025 | 18.43 Mn |
| Sep 30, 2025 | 18.43 Mn |
| Jun 30, 2025 | 182,000.00 |
| Jun 30, 2025 | 182,000.00 |
| Mar 31, 2025 | -10.03 Mn |
| Mar 31, 2025 | -10.03 Mn |
| Dec 31, 2024 | 1.98 Mn |
| Dec 31, 2024 | 1.98 Mn |
| Sep 30, 2024 | -8.31 Mn |
| Sep 30, 2024 | -8.31 Mn |
| Jun 30, 2024 | -10.35 Mn |
| Jun 30, 2024 | -10.35 Mn |
| Mar 31, 2024 | -20.30 Mn |
| Mar 31, 2024 | -20.30 Mn |
| Dec 31, 2023 | 7.47 Mn |
| Dec 31, 2023 | 7.47 Mn |